📊 DYN Key Takeaways
Is Dyne Therapeutics, Inc. (DYN) a Good Investment?
Dyne Therapeutics is a pre-revenue pharmaceutical company with severe operating losses (-$125.3M) and negative free cash flow (-$145.1M), indicating substantial development-stage burn with no commercial traction. While the balance sheet remains solid with $753.1M in cash providing 5+ years of runway, the absence of revenue generation capability and persistent negative returns on assets (-11.2% ROA) present fundamental profitability challenges.
Dyne Therapeutics shows the classic profile of a development-stage biotech: no commercial revenue, deep operating losses, and heavy negative free cash flow, but an unusually strong cash position and very low leverage. Fundamentally, the balance sheet provides meaningful runway to fund R&D, yet the business still depends on future clinical and regulatory execution before its financial model can improve materially.
Dyne Therapeutics, Inc. Key Strengths (DYN)
- Exceptional liquidity with 19.92x current ratio and $753.1M cash reserves
- Low leverage with 0.17x debt-to-equity ratio and minimal debt burden
- Extended cash runway of 5+ years at current burn rate supports continued operations
- Very strong liquidity with $893.37M in cash and a 22.25x current ratio
- Low balance-sheet leverage with debt/equity of 0.15x and equity of $972.13M
- Large asset base relative to liabilities, giving the company flexibility to fund ongoing development
DYN Stock Risks: Dyne Therapeutics, Inc. Investment Risks
- Zero revenue with no commercial product generating sales
- Significant annual cash burn of -$145.1M with negative operating cash flow
- Persistent unprofitability with -$120.9M net loss and negative ROE/ROA metrics
- Long-term sustainability dependent on pipeline success with no near-term profitability visibility
- No revenue base or gross profit, so profitability depends entirely on future commercialization success
- High cash burn with -$403.21M operating cash flow and -$405.13M free cash flow
- Deep losses and negative returns on equity/assets indicate weak current operating economics
Key Metrics to Watch
- Cash burn rate and remaining runway duration
- Revenue generation milestones and product commercialization timeline
- Operating loss trajectory and path to breakeven
- Clinical pipeline advancement and regulatory progress
- Quarterly operating cash burn and remaining cash runway
- Any transition from pre-revenue status toward sustainable product revenue or major milestone income
Dyne Therapeutics, Inc. (DYN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 19.92x current ratio provides a solid financial cushion.
DYN Profit Margin, ROE & Profitability Analysis
DYN vs Healthcare Sector: How Dyne Therapeutics, Inc. Compares
How Dyne Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Dyne Therapeutics, Inc. Stock Overvalued? DYN Valuation Analysis 2026
Based on fundamental analysis, Dyne Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Dyne Therapeutics, Inc. Balance Sheet: DYN Debt, Cash & Liquidity
DYN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Dyne Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3.95 indicates the company is currently unprofitable.
DYN Revenue Growth, EPS Growth & YoY Performance
Dyne Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
DYN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Dyne Therapeutics, Inc. (CIK: 0001818794)
📋 Recent SEC Filings
❓ Frequently Asked Questions about DYN
What is the AI rating for DYN?
Dyne Therapeutics, Inc. (DYN) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are DYN's key strengths?
Claude: Exceptional liquidity with 19.92x current ratio and $753.1M cash reserves. Low leverage with 0.17x debt-to-equity ratio and minimal debt burden. ChatGPT: Very strong liquidity with $893.37M in cash and a 22.25x current ratio. Low balance-sheet leverage with debt/equity of 0.15x and equity of $972.13M.
What are the risks of investing in DYN?
Claude: Zero revenue with no commercial product generating sales. Significant annual cash burn of -$145.1M with negative operating cash flow. ChatGPT: No revenue base or gross profit, so profitability depends entirely on future commercialization success. High cash burn with -$403.21M operating cash flow and -$405.13M free cash flow.
What is DYN's revenue and growth?
Dyne Therapeutics, Inc. reported revenue of N/A.
Does DYN pay dividends?
Dyne Therapeutics, Inc. does not currently pay dividends.
Where can I find DYN SEC filings?
Official SEC filings for Dyne Therapeutics, Inc. (CIK: 0001818794) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DYN's EPS?
Dyne Therapeutics, Inc. has a diluted EPS of $-0.73.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is DYN's fundamental grade?
Based on our AI fundamental analysis in June 2026, Dyne Therapeutics, Inc. has a C grade with 72% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is DYN stock overvalued or undervalued?
Valuation metrics for DYN: ROE of -14.0% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is DYN's AI grade for 2026?
Our dual AI analysis gives Dyne Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is DYN's free cash flow?
Dyne Therapeutics, Inc.'s operating cash flow is $-144.9M, with capital expenditures of $221.0K.
How does DYN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -14.0% (avg: 15%), current ratio 19.92 (avg: 2).